Home › Funds › DAFNA Capital Management LLC › EPRX
DAFNA Capital Management LLC position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
DAFNA Capital Management LLC reported holding 404,567 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$3.7M, representing 0.79% of its reported portfolio and ranking #32 among its reported holdings. DAFNA Capital Management LLC has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How DAFNA Capital Management LLC's EPRX position evolved
DAFNA Capital Management LLC first disclosed a stake in EPRX in Q2 2026 at 225,600 shares (US$1.5M). The position peaked in Q3 2026 at 404,567 shares, worth US$3.7M. Across 2 filings, DAFNA Capital Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 404,567 shares valued at US$3.7M — an increase of 178,967 shares quarter over quarter.. Notable position changes include a 79% increase in Q3 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 225.60K | $1.49M | New |
| Q3 2026 | 404.57K | $3.68M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 72 other funds we track also report a position in EPRX — the largest reported positions include Bellevue Group AG (US$23.6M), Affinity Asset Advisors, LLC (US$15.6M), Vivo Capital, LLC (US$12.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Bellevue Group AG 2.60M sh · $23.62M · Q3 2026
- Affinity Asset Advisors, LLC 1.72M sh · $15.62M · Q3 2026
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $10.92M · Q3 2026
- Caligan Partners LP 1.16M sh · $10.58M · Q3 2026
- PFM Health Sciences, LP 1.13M sh · $10.26M · Q3 2026
- Ikarian Capital, LLC 809.74K sh · $7.37M · Q3 2026
- Seven Fleet Capital Management LP 572.27K sh · $5.21M · Q3 2026
- Redmile Group, LLC 519.88K sh · $4.73M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $3.20M · Q3 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- DV EQUITIES, LLC 276.00K sh · $2.51M · Q3 2026
More on DAFNA Capital Management LLC
FAQ
How long has DAFNA Capital Management LLC held EPRX?
DAFNA Capital Management LLC has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is DAFNA Capital Management LLC's current position in EPRX?
As of Q3 2026, DAFNA Capital Management LLC holds 404.57K shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $3.68M, representing 0.79% of its reported portfolio and ranking #32.
Has DAFNA Capital Management LLC been buying or selling EPRX?
In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC increased its position in EPRX. The position peaked in Q3 2026 at 404.57K shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Bellevue Group AG, Affinity Asset Advisors, LLC, Vivo Capital, LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.